Immunology of VIP: A review and therapeutical perspectives

被引:164
作者
Gomariz, RP [1 ]
Martinez, C [1 ]
Abad, C [1 ]
Leceta, J [1 ]
Delgado, M [1 ]
机构
[1] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain
关键词
D O I
10.2174/1381612013398374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohn's disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this "very important peptide".
引用
收藏
页码:89 / 111
页数:23
相关论文
共 212 条
[1]  
ADELMAN DC, 1991, J ALLERGY CLIN IMMUN, V87, pA260
[2]   Modulating effects of sensory and autonomic neuropeptides on murine splenocyte proliferation and cytokine secretion induced by Leishmania major [J].
Ahmed, AA ;
Mutt, V ;
Nordlind, K .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1999, 21 (03) :507-526
[3]  
AILLET G, 1987, ANN PATHOL, V7, P325
[4]   Colonic enteric nervous system in patients with familial amyloidotic neuropathy [J].
Anan, I ;
El-Salhy, M ;
Ando, Y ;
Forsgren, S ;
Nyhlin, N ;
Terazaki, H ;
Sakashita, N ;
Suhr, OB .
ACTA NEUROPATHOLOGICA, 1999, 98 (01) :48-54
[5]   HEMODYNAMICS OF PELVIC NERVE INDUCED PENILE ERECTION IN THE DOG - POSSIBLE MEDIATION BY VASOACTIVE INTESTINAL POLYPEPTIDE [J].
ANDERSSON, PO ;
BLOOM, SR ;
MELLANDER, S .
JOURNAL OF PHYSIOLOGY-LONDON, 1984, 350 (MAY) :209-224
[6]   EFFECTS OF HIGH INVIVO LEVELS OF VASOACTIVE INTESTINAL POLYPEPTIDE ON FUNCTION OF CIRCULATING LYMPHOCYTES IN HUMANS [J].
ANNIBALE, B ;
FAIS, S ;
BOIRIVANT, M ;
DELLEFAVE, G ;
PALLONE, F .
GASTROENTEROLOGY, 1990, 98 (06) :1693-1698
[7]   VIP RESTORES NATURAL-KILLER-CELL ACTIVITY DEPRESSED BY HEPATITIS-B SURFACE-ANTIGEN [J].
AZZARI, C ;
ROSSI, ME ;
RESTI, M ;
CALDINI, AL ;
CARBONELLA, R ;
CIAPPI, S ;
VIERUCCI, A .
VIRAL IMMUNOLOGY, 1992, 5 (03) :195-200
[8]   Regulation of inducible and neuronal nitric oxide synthase gene expression by interferon-gamma and VIP [J].
Bandyopadhyay, A ;
Chakder, S ;
Rattan, S .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1997, 272 (06) :C1790-C1797
[9]  
Barnes PJ, 1998, PHARMACOL REV, V50, P515
[10]   Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes [J].
Bellinger, DL ;
Lorton, D ;
Horn, L ;
Brouxhon, S ;
Felten, SY ;
Felten, DL .
PEPTIDES, 1997, 18 (08) :1139-1149